在甲状腺局部晚期瘤细胞癌中对索拉费尼布的反应
Andres Pereira1, Diana Parra1, Mauricio Alvarez2
1Facultad de Medicina y Ciencias de la Salud, Universidad Militar Nueva Granada, Bogotá, Cundinamarca, Colombia.
BMJ case reports
|February 20, 2024
概括
一名患有晚期瘤细胞癌的患者在接受索拉费尼布治疗后经历了瘤回归. 这种多酶抑制剂在治疗抗性甲状腺癌的局部病变方面表现出有效性.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 医学研究 医学研究
背景情况:
- 广泛侵袭性瘤细胞癌是一种罕见且具有攻击性的甲状腺恶性瘤.
- 晚期阶段往往涉及甲状腺外延伸和远程转移,这给治疗带来了重大挑战.
研究的目的:
- 报告一个用sorafenib治疗的晚期瘤细胞癌的病例.
- 评估索拉费尼布在患有抗转移性疾病的患者中的疗效.
主要方法:
- 一名70多岁的女性患者患有广泛侵入性的瘤细胞癌,接受了索拉芬尼治疗.
- 治疗决定是基于的折射性和疾病进展,包括局部区域和转移性传播.
主要成果:
- 患者在一年内发展出肺,骨和大脑转移.
- 在开始索拉费尼布治疗后,观察到区域性宫病变回归.
- 索拉费尼布对先进的,耐性细胞癌的活性有所表现.
结论:
- 索拉菲尼布可能是一个可行的治疗选择,用于先进的,耐性细胞癌.
- 多基因酶抑制剂可以在具有挑战性的甲状腺癌病例中诱导局部疾病的回归.
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:27Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
01:20Synthesis and Regulation of Thyroid Hormones
4.6K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
4.6K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K